VaxGen Pharma designs, manufactures and ships vaccines for the pathogens that keep coming back — respiratory, enteric and pandemic. Ten programmes in development, four GMP sites, and a cold chain that holds its temperature across 174 countries.
Dublin, Ireland · Founded 2011 · NASDAQ: VXGN
Every programme we take into the clinic has to survive the same three questions: does it make the right immune response, does it stay potent in the vial, and can we make it at scale if it works. We design for all three from day one.
Adjuvant matching and immunogen geometry are chosen together, then validated in human-relevant challenge models before Phase I. Every candidate carries a defined correlate of protection at entry.
Our liquid-stable formulations hold 36 months at 2–8 °C without a freezer, which is what makes routine immunisation in low-resource districts actually deliverable.
Every candidate is transferred onto our single-use platform at 2,000 L before Phase II, so a successful trial becomes a licensed product on our own lines — not someone else's queue.
Prophylactic, therapeutic and partner-led candidates across six pathogens. Filter by category, or read the whole chart below.
Respiratory syncytial virus · adults 60+
Stabilised prefusion F protein with AS-V3 adjuvant
Pandemic influenza · H5Nx clades
Recombinant HA nanoparticle, stockpile formulation
Seasonal influenza A/B · quadrivalent
mRNA-LNP, strain-updated in 92 days
Dengue serotypes 1–4 · endemic regions
Live-attenuated chimeric backbone
Group B streptococcus · maternal
Capsular polysaccharide glycoconjugate
Pulmonary tuberculosis · post-exposure
Mucosal adenoviral vector, inhaled delivery
Shigella flexneri and sonnei · paediatric
Synthetic bioconjugate, low-cost scale-out
Personalised neoantigen · solid tumours
mRNA-LNP with Auriga Biologics, our LNP in their trial
Rabies · post-exposure prophylaxis
Monoclonal antibody cocktail, co-formulated
Cytomegalovirus · congenital transmission
gB nanoparticle, discovery-stage antigen work
Pipeline shown as at 30 September 2026. Programme codes, stage positions and milestone dates are demonstration content for this template.
Download the pipeline chartFour GMP sites, drug substance through fill-finish, and release testing in-house. That is what lets us promise a pandemic response in 100 days rather than hope for one.
Two isolator filling lines running 24 hours a day, four days a week, under continuous environmental monitoring and Annex 1 grade A conditions.
EU GMP
Ireland · HQ site
Fill-finish, LNP encapsulation and global quality release for every commercial batch.
PIC/S
Singapore · APAC hub
mRNA drug substance at 2,000 L single-use scale, plus regional release for Asia-Pacific.
US FDA
United States · R&D + supply
Recombinant antigen expression and the primary analytical development laboratory.
ANVISA
Brazil · LATAM hub
Regional fill-finish and release, cutting last-mile delivery times across Latin America.
Disposable bioreactor trains cut changeover to under 72 hours between programmes.
Stainless-scale capacity waiting for the first commercial launch volumes.
In-line particle sizing on every lot, with the release spec drafted into the BLA.
Isolator lines, grade A unidirectional airflow and continuous viable monitoring.
At-line analytics remove the traditional end-of-batch wait from the critical path.
Validated −70 °C, −20 °C and 2–8 °C storage with automated excursion response.
Six regional hubs, forty-two local depots and a qualified lane for every destination we ship to. Every shipment carries an independent temperature logger, and every excursion is a deviation we investigate.
−70 °C
mRNA-LNP products move in dry-vapour shippers with 10 days of hold-over, monitored to the minute.
−20 °C
Viral-vector and nanoparticle products, shipped with validated phase-change panels on ocean and air freight.
2–8 °C
Our thermostable formulations, stable for 36 months in a standard vaccine fridge — no freezer required.
Our candidates are built with academic immunology groups, tropical-medicine institutes and public-health agencies who hold the challenge models, the field sites and the epidemiology we cannot replicate in-house.
Zurich, Switzerland
Structure-guided antigen design and human-relevant immune profiling for our RSV and CMV candidates.
Singapore
Controlled human infection models and endemic-site epidemiology for DengueGuard and ShigaShield.
Oslo, Norway
Pandemic stockpile design, strain-watch surveillance and the H5Nx response framework.
São Paulo, Brazil
Phase III field networks across seven countries, plus regulatory navigation for LATAM registration.
Cambridge, Massachusetts
Co-development of a personalised neoantigen candidate, pairing their target discovery with our LNP.
Geneva, Switzerland
Advance purchase commitments for low-income markets, including tiered pricing and dose donation.
One funding structure, one integrated team, one joint steering committee. Four stages from first conversation to first participant dosed — typically inside 14 months.
Six weeks of joint technical diligence on the target, the model and the commercial case.
Bench work on both sides to prove the antigen and the assay translate between labs.
Shared cost, shared risk and pre-agreed milestone payments up to Phase II readout.
A single committee governs protocol, safety review and publication rights.
VaxGen lists on NASDAQ and reports quarterly. Two Phase III assets are within eighteen months of filing, four sites are already licensed, and 34% of revenue goes back into the bench.
Prices, financials and events shown are illustrative demonstration content for this template and are not an offer of securities or investment advice.